We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GMED - GenoMed Inc.
GMED 65.61-0.5%Jun 14 4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: jmhollen8/21/2006 10:10:06 AM
   of 347
GenoMed's Third Horse with Presumed West Nile Virus Encephalitis Is Better in 24 Hours

David W. Moskowitz MD
St. Louis, Missouri
Tel. 314.983.9938

ST. LOUIS—August 21, 2006--GenoMed (OTC Pink Sheets GMED), a Next Generation Disease Management company that uses genomics to solve diseases in as many species as possible, today announced that the third horse in its expanded trial for West Nile virus encephalitis recovered markedly within 24 hours after starting GenoMed's treatment.

On Thursday afternoon last week, a horse owner in Fresno, California telephoned GenoMed to say that her horse could no longer walk straight and was falling down. The horse had not been vaccinated for West Nile virus, and the diagnosis by the veterinarian was presumed West Nile virus encephalitis.

Within 24 hours of the first dose of GenoMed's treatment, the horse was chasing other horses away from his food, which they had been eating while he was sick.

West Nile virus encephalitis affects horses more severely than people, and the odds of recovery are slimmer. As with people, recovery from viral encephalitis usually takes at least a week. Recovery within 24 hours, like GenoMed's three horses and most of GenoMed's human patients, is extremely unusual.

Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, "It's always thrilling to see a clinical trial showing great results. Every trial is really just a gamble. Fortunately, this one seems to be continuing to pay off. All our evidence for the past four years, in humans, birds, and now horses, has been extremely positive."

GenoMed's treatment success rate for WNV encephalitis in people is currently 87% (20 of 23 patients improved rapidly). A small case series involving the company's first 8 patients was published in a peer-reviewed medical journal in 2004.

About GenoMed

Anyone can download the human protocol for West Nile virus for free from GenoMed's website,, at any time. Horse owners are encouraged to contact Dr. Moskowitz directly (see contact information above) to discuss dosing.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext